FSFunctional Specification
The critical initiation phase of pharmaceutical capital projects that determines technical viability, regulatory risk, and investment logic before design begins.

On this page · 8 sections
How does FS apply to your shop floor?
Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.
01Defining the Feasibility Study (FS)
In the context of pharmaceutical and biotech capital projects, a Feasibility Study (FS) is the primary investigation conducted at the earliest stage of the project lifecycle. Its objective is to determine if a proposed investment—such as a new manufacturing facility, a line expansion, or a significant process upgrade—is technically achievable, economically viable, and compliant with regulatory expectations 2. It serves as the 'Go/No-Go' gate that prevents organizations from committing millions in capital to projects that lack a clear path to success.
A well-executed Feasibility Study does not attempt to solve every engineering detail. Instead, it focuses on identifying 'deal-breakers'—technical constraints, site limitations, or regulatory hurdles that could render the project non-viable. The output is typically a recommendation to the Board or Investment Committee, backed by a range of CAPEX (Capital Expenditure) and OPEX (Operating Expenditure) estimates, a preliminary schedule, and a high-level risk register 3.
02Where the FS Sits in the Project Lifecycle
The Feasibility Study occupies 'Stage 1' of the pharmaceutical project lifecycle 2. It is distinct from and precedes Conceptual Design, though the two are frequently blurred in smaller projects. Understanding the boundary is essential for effective stage-gate governance.
- Project Initiation: The 'Idea' phase where business needs are identified.
- Feasibility Study (FS): 'Is this a good idea?' Focus on viability and broad options.
- Conceptual Design: 'Identifying the best option.' Translating the idea into layouts and PFDs.
- Basic Design / FEED: 'How do we build it?' Detailed specifications and long-lead procurement.
- Detailed Engineering: The final design for construction and installation.
From a regulatory perspective, the FS aligns with the very beginning of 'Stage 1: Process Design' in the FDA's three-stage process validation lifecycle 1. While the FS is a business-driven activity, the technical decisions made here—such as choosing between batch and continuous manufacturing—establish the 'Design Space' that will eventually be qualified. Skipping this stage or rushing through it often leads to 'Scope Creep' in later phases, as fundamental questions about capacity or site suitability remain unanswered while expensive detailed design is underway 4.
03Process Options and Capacity Modeling
The core of any pharmaceutical feasibility study is the translation of a product portfolio into physical requirements. This begins with capacity modeling. The study must determine if the target volumes can be achieved within the proposed shift patterns, equipment sizes, and cycle times 3.
Key considerations in process feasibility include:
- Technology Selection: Comparing traditional stainless steel vs. single-use technology (SUT), or batch vs. continuous manufacturing (ICH Q13).
- Throughput Analysis: Modeling batch sizes, turnaround times, and cleaning requirements (CIP/SIP) to ensure the facility doesn't become a bottleneck.
- Material Compatibility: Assessing the handling requirements for highly potent APIs (HPAPI), flammable solvents, or light-sensitive compounds.
- Future-Proofing: Determining the level of 'spare capacity' or modularity needed to accommodate future products not yet in the pipeline.
Mistakes in capacity modeling during the FS are among the most expensive to fix. If the batch size is sized incorrectly for the utility loads (e.g., purified water demand during peak cleaning cycles), the facility may never reach its rated nameplate capacity without significant rework of the underlying infrastructure.
04Site and Utilities Assessment
A feasibility study must evaluate the 'Host' for the new process. This could be a 'Greenfield' site (raw land), a 'Brownfield' site (existing industrial site), or an 'Interior Fit-out' (within an existing shell). Each carries vastly different risk profiles regarding utilities and infrastructure 5.
The FS examines the 'Black Utilities' (standard industrial utilities like electricity, natural gas, and city water) and their capacity to support the 'Clean Utilities' (Purified Water, WFI, Clean Steam, Process Gases). Specifically, the study looks for:
- Power Reliability: Does the local grid support the uptime required for sensitive biologics, or is a dedicated substation and backup generation required?
- Water Quality and Quantity: Can the local municipal supply meet the raw water demand for WFI generation, especially during peak demand periods?
- Environmental Impact: Wastewater treatment capacity and emissions permits required for the specific process chemistry.
- Structural Suitability: For interior fit-outs, can the existing slab support the weight of heavy equipment like bioreactors, tablet presses, or lyophilizers?
05Regulatory and Compliance Constraints
In the life sciences, feasibility is as much about 'Permittability' as it is about engineering. The FS must identify the regulatory pathway for the product in its target markets (FDA, EMA, NMPA, etc.) 3. This includes determining the required Cleanroom Grades (ISO/EU) and the containment strategies necessary to prevent cross-contamination.
A critical output of the FS is the 'Regulatory Roadmap,' which outlines:
- Zoning Requirements: High-level segregation strategy for allergens, penicillins, or live viruses.
- Glove/Barrier Strategy: Preliminary decision on whether to use isolators, RABS (Restricted Access Barrier Systems), or traditional cleanrooms.
- Qualification Strategy: How the project will align with Annex 15 and the company's Validation Master Plan (VMP).
- Audit Trail Requirements: Identifying which processes will require 21 CFR Part 11 compliant digital records.
06Cost Estimates and Project Risk
The financial deliverable of a Feasibility Study is typically a 'Class 4' or 'Class 5' estimate (per AACE International standards), which usually carries an accuracy range of +50% / -30% 4. The goal is not precision, but a 'Budget Envelope' that allows for an investment decision.
Parallel to the cost estimate is the Project Risk Register. Unlike the Quality Risk Management (QRM) activities that happen during design, the FS risk register focuses on macro-risks:
- Supply Chain Risk: Long-lead times for critical equipment (e.g., custom bioreactors or high-speed fillers).
- Geopolitical Risk: Regulatory changes or trade barriers in target markets.
- Technical Risk: Novel process technology that has not been proven at scale.
- Resource Risk: Availability of skilled labor for construction and eventual operation in the selected geography.
07Sign-off and Feeding the URS
A Feasibility Study is typically signed off by a cross-functional group of senior stakeholders, including Finance, Operations, Engineering, and Quality Assurance 2. This sign-off represents the 'Authorization to Spend' on the next phase: Conceptual Design and the development of the User Requirements Specification (URS).
The FS directly feeds the URS by establishing the 'Business Requirements' that the URS will formalize. For example, if the FS determines that a 24/7 continuous process is necessary for viability, the URS must then specify the automated diversion valves and PAT (Process Analytical Technology) requirements to support that state of control. Without a solid FS, the URS often lacks the context needed to make informed technical trade-offs.
08Common Mistakes in Pharma Feasibility Studies
Even experienced teams fall into predictable traps during the feasibility phase. The most common including:
- Optimistic Capacity Modeling: Assuming 100% equipment availability and ignoring the time required for cleaning validation and line clearance between batches.
- Ignoring 'Hidden' Infrastructure: Budgeting for the process equipment but underestimating the cost of the HVAC, mezzanine structures, and effluent treatment required to support it.
- Late QA Involvement: Waiting until Conceptual Design to bring in Quality Assurance, only to find that the proposed layout violates basic segregation principles.
- Underestimating Regulatory Timelines: Factoring in the construction schedule but ignoring the 'Regulatory Clock'—the time required for agency inspections and license approvals before commercial manufacturing can begin.
Frequently asked questions
Q.What is the difference between a Feasibility Study and Conceptual Design?+
The Feasibility Study (FS) focuses on 'If'—if the project makes sense commercially, technically, and regulatory. Conceptual Design focuses on 'How'—developing the specific layouts, process flow diagrams, and zoning strategies for the selected option. FS identifies options; Conceptual Design develops the chosen one.
Q.Who is responsible for the Feasibility Study?+
It is usually led by a Project Manager or a Business Development lead, with heavy input from Process Engineering and Finance. Quality Assurance (QA) must review the study to ensure the proposed regulatory roadmap is sound, but they do not typically 'own' the document.
Q.Does a Feasibility Study need to be validated?+
No. The FS is a business and engineering planning document. However, it is a critical input for Design Qualification (DQ). The data used in the FS (such as clinical trial success rates or market forecasts) is not 'GMP data,' but the technical conclusions (such as required batch sizes) become the basis for GxP requirements in the URS.
Q.How accurate should the cost estimate be in an FS?+
Typically, a Feasibility Study aims for a +50% / -30% accuracy (AACE Class 4/5). The goal is to provide enough confidence for an 'Initial Investment Decision' or to fund the Conceptual Design phase, where a more accurate Class 3 estimate will be developed.
Primary sources
Further reading
- User Requirements Specification (URS)The next step after feasibility: defining the specific needs the system must meet.
- Design Qualification (DQ)The formal proof that the proposed design satisfies the URS and FS requirements.
- EU GMP Annex 15The regulatory framework for qualification and validation that governs the project lifecycle.
- Process Validation LifecycleUnderstanding how Stage 1 (Design) begins with the feasibility decisions.
- GAMP 5The framework for validated IT systems, where 'FS' often refers to a Functional Specification.
Explore this topic
FS sits inside 2 overlapping topic clusters in our glossary. Every neighbour is one click away.
Electronic records, signatures, audit trail and ALCOA+ data-integrity principles.
URS-through-PQ lifecycle, GAMP 5 categorisation and CSA's modern alternative.
Want to see how FS could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.
